GEOVAX REPORTS PROGRESS IN AIDS VACCINE TRIALS

GeoVax Labs has reported positive early results from two ongoing AIDS prevention Phase I human vaccine trials. Results from the first low-dose trial indicate a good safety profile as well as positive immune responses in human volunteers receiving GeoVax's AIDS vaccine. Results from a second larger full-dose trial also indicate a good safety profile in participants. The GeoVax vaccines being tested are designed to prevent the development of AIDS caused by HIV.

Early results from GeoVax's AIDS vaccine trials demonstrate a very acceptable safety profile in an ongoing low-dose trial begun in April 2006. They also indicate that as little as one-10th of a full dose of GeoVax's vaccine stimulates potentially protective anti-HIV-1 immune responses in the majority of vaccine recipients. Data suggest that a full dose of the vaccine will stimulate an even better immune response in recipients participating in the full dose trial, and final data is expected later this year. Finally, the results support accelerated plans for a large Phase II human trial including more than 300 participants in North and South America.

The full-dose trial has enrolled 36 volunteers, 30 of which received the vaccine, while six control subjects received a placebo. The full-dose of AIDS vaccine approximates the dose size that protected 96 percent of nonhuman primates in preclinical studies.

The trials are being conducted by the HIV Vaccine Trials Network, which is funded and supported by the NIH. Preclinical work enabling development of the clinical evaluation of GeoVax's vaccines was also funded and supported by the NIH's National Institute of Allergy and Infectious Diseases.